
For physical and emotional health, new mums should exercise two hours weekly
Experts say whatever amount of exercise new mothers can manage will help both physical and mental health. — JULIAN STRATENSCHULTE/dpa
New mothers should aim for two hours of moderate to vigorous exercise every week, such as brisk walking or cycling, researchers say.
Getting back to exercise in the first 12 weeks after birth will help boost both physical and mental health and improve sleep, according to a study.
After looking at existing research, experts produced a 'strong recommendation' for new mothers to spend at least 120 minutes a week doing such exercise, spread over four or more days of the week.
This should incorporate a variety of aerobic and resistance training, they said.
Resistance training includes things such as using gym machines or doing exercises including sit ups, squats, push ups, leg raises and planks.
Writing in the British Journal of Sports Medicine, the new guidance from the Canadian Society for Exercise Physiology also 'strongly' recommends women do daily pelvic floor muscle training to reduce the risk of urinary incontinence.
Women should also try their best to develop a healthy sleep routine (such as avoiding screen time and maintaining a dark, quiet environment before bed) to support their mental health.
The Canadian researchers said: 'Beginning or returning to MVPA (moderate to vigorous physical activity) in the first 12 weeks following childbirth, and better quality sleep, are associated with improved mental health.
'Postpartum women and people who follow this guideline for physical activity, sedentary behaviour and sleep will likely experience a large improvement in their psychological well-being (ie reduction in the prevalence of depression, symptoms of depression and anxiety); pelvic floor health (ie reduction in the risk of urinary incontinence); musculoskeletal health (ie reduction in low back and pelvic girdle pain symptoms and severity); cardiometabolic health (ie improvement in weight, body mass index and blood lipids); and a reduction in fatigue, while not experiencing adverse effects (eg reduced breastmilk supply or injury).'
Safe after healed
The team said returning to running and resistance training is generally safe once a woman is healed from their baby's birth, including Caesarean section.
They added: 'It is essential to acknowledge that infant feeding and care significantly impacts daily life, including sleep, thus these recommendations may not always be achievable, and at times specific recommendations within this guideline will not align with current circumstances.'
However, the team said 'any progress – even if small – in meeting physical activity targets can improve maternal physical and mental health, and any reductions in sedentary behaviour may improve cardiometabolic health.'
Justine Roberts, founder and chief executive of British parenting website Mumsnet, said: 'Clear, evidence-based guidance on postpartum exercise is long overdue, and it's encouraging to see recommendations that prioritise the well-being of new mothers, even if some of them seem wildly optimistic about what looking after a newborn entails.
'As Mumsnet users will attest, 'developing a healthy sleep routine' is much easier said than done.
'However, it's crucial that this guidance doesn't become yet another stick to beat new mums with.
'Many of them are already stretched to their limits, and advice like this isn't always helpful if you don't have the practical means to follow it.'
For the study, experts looked at 574 lots of research and how these related to reduced breast milk quality or quantity, depression and anxiety, urinary incontinence, fear of movement, fatigue, injury, and poor infant growth and development. – dpa
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Star
3 days ago
- The Star
French lawmakers approve assisted dying bill, paving the way for approval
FILE PHOTO: A French flag flies over the National Assembly in Paris, France, April 18, 2025. REUTERS/Abdul Saboor/File Photo PARIS (Reuters) -French lower house lawmakers approved a bill on Tuesday to legalise assisted dying, paving the way for France to become the latest European nation to allow terminally ill people to end their lives. The final passage of the bill remains some way off, with the text now heading to the Senate. However, the legislation is expected to pass, with polls showing more than 90% of French people in favour of laws that give people with terminal diseases or interminable suffering the right to die. French President Emmanuel Macron called the vote in the National Assembly "an important step." The bill, which was approved in parliament by 305 votes to 199, provides the right to assisted dying to any French person over the age of 18 suffering from a serious or incurable condition that is life-threatening, advanced or terminal. The person, who must freely make their decision, must also have constant physical or psychological suffering that cannot be alleviated. Lawmakers stipulated that psychological suffering alone would not be enough to end one's life. The patient can administer the lethal dose themselves or by an accredited medical professional if they are physically unable. Healthcare workers who object to doing so are free to opt out. Anyone found to have obstructed someone's right to die can face a two-year prison sentence and a 30,000 euro fine. Laws to enable assisted dying are gathering steam across Europe. In November, British lawmakers voted in favour of allowing assisted dying, paving the way for Britain to follow countries such as Australia, Canada and some U.S. states in what would be the biggest social reform in a generation. In March, the Isle of Man, a self-governing British Crown Dependency off northwest England, approved an assisted dying bill, potentially making the island the first place in the British Isles where terminally ill people could end their lives. "France is one of the last countries in Western Europe to legislate on this issue," leftist lawmaker Olivier Falorni told Reuters. "We are in a global process ... France is behind, and I hope we will do it with our own model." (Reporting by Elizabeth Pineau and Gabriel Stargardter; additional reporting by Zhifan Liu and Makini Brice; Editing by Nia Williams)


The Star
3 days ago
- The Star
Britain launches world's first gonorrhoea vaccination programme
The resurgence of gonorrhoea in Britain has prompted the government there to start the world's first vaccination programme against the STD. — AFP Health authorities in England announced on May 21 (2025) the rollout of a world-first vaccine programme for gonorrhoea, amid record levels of the sexually-transmitted disease (STD). Gonorrhoea cases in England in 2023 topped 85,000 – the highest number since records began in 1918 – with doctors warning of rising levels of antibiotic resistance. Chief executive Richard Angell of the Terrence Higgins Trust, Britain's leading HIV (human immunodeficiency virus) and sexual health charity, hailed the initiative as a 'game changer'. 'This alone could cut 40% of new gonorrhoea cases,' he said. National Health Service (NHS) England's primary and community care director Dr Amanda Doyle said it would be the world's 'first' routine vaccination programme for the disease. She described it as a 'huge step forward for sexual health', adding that it would also help 're- duce the rising rates of antibiotic resistance strains of the bacteria'. The programme deploys an existing jab normally used to protect children against the meningococcal B disease, a serious bacterial infection that can cause meningitis and sepsis. Known as 4CMenB, it is part of the routine British childhood vaccination programme given to babies at eight weeks, 16 weeks and one year of age. Under the new programme, the jabs will be offered to those considered most at risk: gay and bisexual men with a recent history of multiple sexual partners or a bacterial sexually-transmitted infection. 'This vaccination programme is a hugely welcome intervention at a time when we're seeing very concerning levels of gonorrhoea, including antibiotic-resistant gonorrhoea,' said NHS consultant epidemiologist Dr Sema Mandal. 'In 2023, we saw gonorrhoea diagnoses reach their highest since records began in 1918,' added the deputy director of the UK Health Security Agency (UKHSA). During appointments, patients will also be offered jabs for mpox, human papillomavirus (HPV), and hepatitis A and B. For decades, gonorrhoea, nicknamed 'the clap', along with syphilis, have been regarded as Victorian-era diseases largely eradicated due to modern diagnosis and medicine. Like gonorrhoea, however, the number of syphilis cases has also seen a resurgence in Britain. In 2023, 9,513 cases were reported, a more than 9% increase on the previous year and the highest number since 1948, according to UKHSA statistics. – AFP


Malaysian Reserve
3 days ago
- Malaysian Reserve
Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada
ETOBICOKE, ON, May 27, 2025 /CNW/ — Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch in Canada of Gen-Clozapine orally disintegrating tablets (ODT) (12.5 mg, 25 mg, 50 mg, 100 mg and 200 mg), providing a new treatment option for treatment-resistant schizophrenia patients. This marks the first availability in Canada of an orally disintegrating tablet of clozapine, which is the only approved antipsychotic for treatment-resistant schizophrenia1. It is estimated that 25% to 30% of individuals with schizophrenia meet the criteria for treatment-resistant schizophrenia.1 Dr. Ofer Agid, Medical Head of Ambulatory Services in the Schizophrenia Division at the Centre for Addiction and Mental Health (CAMH) in Toronto, commented, 'The introduction of Gen-Clozapine is welcome news for patients and physicians alike as this new clozapine formulation rapidly disintegrates when placed on the tongue or can be chewed, which provides a new option for some patients who may need it. This also gives physicians an alternative to the current tablet dosage form.' Gen-Clozapine has been available in tablet form (not orally disintegrating) since 2003. Viatris has provided access to this medicine, and related care, to thousands of Canadian patients through the Gen-Clozapine Access Network (GenCAN) for over 18 years. Viatris Canada's Country Manager Jeffrey Long commented, 'The launch of Gen-Clozapine orally disintegrating tablets demonstrates further evidence of our commitment to providing diversified treatment options to patients and healthcare professionals in Canada. Viatris' strong heritage in mental health, and experience with clozapine specifically, puts us in an excellent position to provide access to this new formulation which will impact patient treatment.' Gen-Clozapine orally disintegrating tablets are available by prescription only and through the GenCAN patient support program. Through GenCAN, Viatris is committed to patient safety, continued advancement of clinical knowledge and applying technology solutions to simplify monitoring practices. The program supports more than 12,000 active patients across Canada, collaborating with healthcare teams for the safe and effective use of Gen-Clozapine. For more information, please consult the Product Monograph at References: Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M (September 2017). 'Guidelines for the Pharmacotherapy of Schizophrenia in Adults'. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie. 62 (9): 604–616. About Viatris Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at and and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter). Forward-Looking StatementsThis statement includes statements that constitute 'forward-looking statements.' These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements regarding new product launches. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; Viatris' failure to achieve expected or targeted future financial and operating performance and results; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, tariffs and trade restrictions, inflation and exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.